Skip to main content
Caplight Logo









AUTOTAC Bio

AUTOTAC Bio

Private
SeoulHealthcare & Life Scienceshttp://autotacbio.com/

Last Round

Series B

Mar 1, 2020

Total Funding Raised

$20.8M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

AUTOTAC Bio is a biotechnology company that develops protein target decomposition therapeutics using its proprietary autophagy-targeting chimera (AUTOTAC) platform technology.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

targeted protein degradationTPDautophagy-targeting chimeraAUTOTACdrug discovery platformundruggable targetsbifunctional moleculeschemical biologyprotein degraderPROTAConcology drug developmentneurodegenerative diseasebiotech licensingsmall-molecule therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AUTOTAC Bio Comparables

Compare AUTOTAC Bio with similar companies based on industry and business-model similarity.

AUTOTAC Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Automera
89%
PAQ Therapeutics
85%
Amphista Therapeutics
83%

AUTOTAC Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 1, 2020
Series AJun 1, 2019

AUTOTAC Bio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 19, 2026

    Monthly visitors increased 153% MoM, reaching 1.4K.

  • May 2, 2025

    Monthly visitors grew 110% MoM, reaching 998.

AUTOTAC Bio Filings

Explore SEC and related filing metadata, where available.

AUTOTAC Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about AUTOTAC Bio's valuation, stock price, and market status.

Is AUTOTAC Bio a public or private company?

AUTOTAC Bio is a private company.

What is the current stock price of AUTOTAC Bio?

AUTOTAC Bio is a private company with no public stock price. No recent secondary market data is available.

How much is AUTOTAC Bio worth (valuation)?

Valuation information for AUTOTAC Bio is not publicly available.

Can I buy AUTOTAC Bio stock?

AUTOTAC Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was AUTOTAC Bio's last funding round?

AUTOTAC Bio's most recent funding round was Series B on March 1, 2020.

Who are the main investors in AUTOTAC Bio?

Key investors in AUTOTAC Bio include Shinhan Venture Investment, DAYLI Partners, Seoul National University Technology Holdings, Mirae Asset Venture Investment, AJU IB Investment.

Will AUTOTAC Bio IPO soon?

No public IPO plans have been announced for AUTOTAC Bio.

How can I track AUTOTAC Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AUTOTAC Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeoul
Employee Range1
Year Founded2018
Last FundingMar 1, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?